- Brazilian Ministério da Saúde Approves Marketing of Sonoma Pharmaceuticals' Products: Lasercyn™, Gramaderm®, Epicyn™ and Pediacyn™
- Brazilian Dermatology Market Second Largest in the World Behind the United States
PETALUMA, Calif., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, today announced the issuance of regulatory approvals by the Brazilian Ministério da Saúde for seven of Sonoma's non-steroidal and non-antibiotic
topical dermatology products:
- Gramaderm® Hydrogel - intended as a skin cleanser after treatment of mild to moderate acne.
- Gramaderm® - intended as a skin cleanser in a hydrogel vehicle after treatment of mild to moderate acne.
- Epicyn™ - intended as a scar treatment.
- Pediacyn™ - intended as an atopic dermatitis treatment.
- Pediacyn™ Gel - intended as an atopic dermatitis treatment in a gel vehicle.
- Lasercyn™ - intended as a skin cleanser following cosmetic procedures such as laser skin resurfacing.
- Lasercyn™ Hydrogel - intended as a skin cleanser in a hydrogel vehicle following cosmetic procedures such as laser skin resurfacing.
"My Brazilian counterparts now have
treatment options that can either replace or complement the standard protocols. In my practice I use Sonoma's products for healing and as a steroid-sparing agent, anti-pruritic and anti-inflammatory," said Dr. Miriam Bettencourt, assistant clinical professor of dermatology at the University of Nevada and adjunct professor of dermatology at Touro University in Las Vegas. "Having studied medicine in Brazil and with many of my colleagues practicing dermatology in Brazil, Sonoma's new approvals should provide additional non-steroidal and non-antibiotic alternatives much like I use in here in the United States."
Sonoma Pharmaceuticals is currently seeking to partner with a Brazilian healthcare company relative to licensing these newly approved products in the Brazilian dermatology space.
"We see the Brazilian dermatology market as being highly lucrative in terms of ongoing ramping revenue," said Bruce Thornton, Sonoma's VP of international sales. "Brazilian dermatologists are cutting edge when it comes to general dermatology and aesthetic procedures, and the addition of seven new hypochlorous acid-based products provides new alternatives for physicians worried about the side effects of topical steroids and resistance issues with the overuse of antibiotics."
About the Brazilian Dermatology Market
According to BCC Research, skin conditions are among the most common health problems
in most national populations, collectively exceeding the prevalence of conditions such as obesity, hypertension and cancer. The considerable costs of skin diseases include physician visits, hospital care, prescription drugs and over-the-counter products for treating or managing these conditions, as well as indirect costs due to productivity losses.
The global market for skin disease treatment technologies is estimated to reach $20.4 billion in 2020. The U.S market is the largest segment and should reach $8.6 billion in 2020. The BRIC (Brazil, Russia, India, China) countries are the fastest growing region of the global dermatology market
and should total more than $4.6 billion by 2020.
About Sonoma Pharmaceuticals, Inc.
Sonoma is a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care. The company's products, which are sold throughout the United States and internationally, have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses. The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com.
Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its
subsidiaries (the "Company"). These forward-looking statements are identified by the use of words such as "believe," "achieve," and "strive," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the Company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company's products will not be as large as expected, the Company's products will not be able to penetrate one or more targeted
markets, revenues will not be sufficient to fund further development and clinical studies, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. The Company disclaims any obligation to update these forward-looking statements, except as required by law.
Sonoma®, Lasercyn™, Gramaderm®, Epicyn™, Pedicayn™ and Microcyn® Technology are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.
Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.
VP of Public and Investor Relations
Source: Sonoma Pharmaceuticals, Inc.
News Provided by Acquire Media